Can Eli Lilly Stock Rebound After A 10% Drop Over Alzheimer’s Drug?
- Monday, March 22, 2021, 7:10
- Market
- Add a comment
The stock price of Eli Lilly & Company has seen a 10% drop over the last five trading days, after the company announced mixed results from clinical trials of Donanemab, a drug for the treatment of Alzheimer’s disease. While the drug met the primary endpoint, it failed to meet a more important…
About the Author
admin123 has written 23527 stories on this site.
